138 related articles for article (PubMed ID: 35615365)
21. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
23. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
[TBL] [Abstract][Full Text] [Related]
24. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
Zuo F; Abolhassani H; Du L; Piralla A; Bertoglio F; de Campos-Mata L; Wan H; Schubert M; Cassaniti I; Wang Y; Sammartino JC; Sun R; Vlachiotis S; Bergami F; Kumagai-Braesch M; Andréll J; Zhang Z; Xue Y; Wenzel EV; Calzolai L; Varani L; Rezaei N; Chavoshzadeh Z; Baldanti F; Hust M; Hammarström L; Marcotte H; Pan-Hammarström Q
Nat Commun; 2022 May; 13(1):2670. PubMed ID: 35562366
[TBL] [Abstract][Full Text] [Related]
25. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.
Wang Z; Zhao Z; Cui T; Huang M; Liu S; Su X; Li G; Song T; Li W; Zhong N; Xu M; Yang X; Huang W
Emerg Microbes Infect; 2022 Dec; 11(1):829-840. PubMed ID: 35230230
[TBL] [Abstract][Full Text] [Related]
26. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
27. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
28. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.
Benning L; Klein K; Morath C; Bartenschlager M; Kim H; Buylaert M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Schaier M; Speer C
Front Immunol; 2022; 13():840136. PubMed ID: 35309320
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients.
Hastert FD; Henss L; von Rhein C; Gerbeth J; Wieters I; Borgans F; Khodamoradi Y; Zacharowski K; Rohde G; Vehreschild MJGT; Schnierle BS
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632624
[TBL] [Abstract][Full Text] [Related]
30. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
31. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
32. Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.
Jawalagatti V; Kirthika P; Hewawaduge C; Yang MS; Park JY; Oh B; Lee JH
Mol Ther; 2022 May; 30(5):1926-1940. PubMed ID: 35123065
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Neutralizing Antibodies against SARS-CoV-2 Variants after Infection and Vaccination Using a Multiplexed Surrogate Virus Neutralization Test.
Lynch KL; Zhou S; Kaul R; Walker R; Wu AH
Clin Chem; 2022 May; 68(5):702-712. PubMed ID: 35018416
[TBL] [Abstract][Full Text] [Related]
34. Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine.
Komissarov AA; Dolzhikova IV; Efimov GA; Logunov DY; Mityaeva O; Molodtsov IA; Naigovzina NB; Peshkova IO; Shcheblyakov DV; Volchkov P; Gintsburg AL; Vasilieva E
J Immunol; 2022 Mar; 208(5):1139-1145. PubMed ID: 35101893
[TBL] [Abstract][Full Text] [Related]
35. Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant.
Yu X; Qi X; Cao Y; Li P; Lu L; Wang P; Feng Y; Yang J; Wei H; Guo L; Sun M; Liu Q; Lv J; Feng Y
Emerg Microbes Infect; 2022 Dec; 11(1):749-752. PubMed ID: 35176972
[TBL] [Abstract][Full Text] [Related]
36. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.
Song S; Zhou B; Cheng L; Liu W; Fan Q; Ge X; Peng H; Fu YX; Ju B; Zhang Z
Virol J; 2022 Jan; 19(1):2. PubMed ID: 34983583
[TBL] [Abstract][Full Text] [Related]
37. Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques.
Deng W; Lv Q; Li F; Liu J; Song Z; Qi F; Wei Q; Yu P; Liu M; Zhou S; Zhang Y; Gao H; Wang N; Jia Z; Gao K; Liu J; Xiao C; Shang H; Wang X; Bao L; Qin C
Signal Transduct Target Ther; 2022 Apr; 7(1):124. PubMed ID: 35436986
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
Choi A; Koch M; Wu K; Chu L; Ma L; Hill A; Nunna N; Huang W; Oestreicher J; Colpitts T; Bennett H; Legault H; Paila Y; Nestorova B; Ding B; Montefiori D; Pajon R; Miller JM; Leav B; Carfi A; McPhee R; Edwards DK
Nat Med; 2021 Nov; 27(11):2025-2031. PubMed ID: 34526698
[TBL] [Abstract][Full Text] [Related]
39. Strategies and safety considerations of booster vaccination in COVID-19.
Meng H; Mao J; Ye Q
Bosn J Basic Med Sci; 2022 Jun; 22(3):366-373. PubMed ID: 35366790
[TBL] [Abstract][Full Text] [Related]
40. Thinking beyond Vaccination: Promising Add-On Strategies to Active Immunization and Vaccination in Pandemics-A Mini-Review.
Tatzber F; Wonisch W; Resch U; Strohmaier W; Lindschinger M; Mörkl S; Cvirn G
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
